Lysine Stress Randomized Trial Evidence Table

Structured evidence table for Lysine Stress Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Lysine Stress Randomized TrialIn contrast, intensive glucose lowering initiated after prolonged hyperglycemic exposure in type 2 diabetes yielded no significant cardiovascular benefit despite achieving guideline targets, as demonstrated in the VADT and ACCORD trials [,].3Cheng Cheng (2026)Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
Lysine Stress Randomized TrialIn ACCORD, intensive glycemic control was additionally associated with increased all‐cause mortality, leading to early termination of that treatment arm [].3Cheng Cheng (2026)Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
Lysine Stress Randomized TrialBenefit endures when the exposure is brief, and risk endures when it is prolonged.3Cheng Cheng (2026)Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
Lysine Stress Randomized Trial1 2 3 4 4 The Diabetes Control and Complications Trial (DCCT) and its Epidemiology of Diabetes Interventions and Complications (EDIC) follow‐up demonstrated that a mean of 6.5 years of intensive glycemic control in type 1 diabetes conferred cardiovascular protection that peaked within the first decade after glucose convergence between treatment groups and left a smaller, lasting legacy [,].3Cheng Cheng (2026)Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
Lysine Stress Randomized TrialMethylglyoxal (MGO), a highly reactive 1,2-dicarbonyl, is generated by all three principal pathways of advanced glycation end product (AGE) synthesis in type 2 diabetes mellitus (T2DM)-the Hodge, Namiki, and Wolff pathways-and by the non-enzymatic degradation of glycolytic triose phosphates.4Fernandez EC (2026)Methylglyoxal as a Convergent Mediator of Diabetic Complications: Generation, Protein Targets, Tissue Distribution, and Therapeutic Reduction-A Clinically Oriented Mechanistic Synthesis.
Lysine Stress Randomized TrialIt is the principal substrate of the glutathione-dependent GLO1/GLO2 glyoxalase system and the main source of the hydroimidazolone-1 (MG-H1) adduct, and it directly modifies intracellular proteins across multiple tissues.4Fernandez EC (2026)Methylglyoxal as a Convergent Mediator of Diabetic Complications: Generation, Protein Targets, Tissue Distribution, and Therapeutic Reduction-A Clinically Oriented Mechanistic Synthesis.
topicLysine Stress Randomized Trial
claimIn contrast, intensive glucose lowering initiated after prolonged hyperglycemic exposure in type 2 diabetes yielded no significant cardiovascular benefit despite achieving guideline targets, as demonstrated in the VADT and ACCORD trials [,].
evidence level3
citationCheng Cheng (2026)
sourceMetabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
topicLysine Stress Randomized Trial
claimIn ACCORD, intensive glycemic control was additionally associated with increased all‐cause mortality, leading to early termination of that treatment arm [].
evidence level3
citationCheng Cheng (2026)
sourceMetabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
topicLysine Stress Randomized Trial
claimBenefit endures when the exposure is brief, and risk endures when it is prolonged.
evidence level3
citationCheng Cheng (2026)
sourceMetabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
topicLysine Stress Randomized Trial
claim1 2 3 4 4 The Diabetes Control and Complications Trial (DCCT) and its Epidemiology of Diabetes Interventions and Complications (EDIC) follow‐up demonstrated that a mean of 6.5 years of intensive glycemic control in type 1 diabetes conferred cardiovascular protection that peaked within the first decade after glucose convergence between treatment groups and left a smaller, lasting legacy [,].
evidence level3
citationCheng Cheng (2026)
sourceMetabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
topicLysine Stress Randomized Trial
claimMethylglyoxal (MGO), a highly reactive 1,2-dicarbonyl, is generated by all three principal pathways of advanced glycation end product (AGE) synthesis in type 2 diabetes mellitus (T2DM)-the Hodge, Namiki, and Wolff pathways-and by the non-enzymatic degradation of glycolytic triose phosphates.
evidence level4
citationFernandez EC (2026)
sourceMethylglyoxal as a Convergent Mediator of Diabetic Complications: Generation, Protein Targets, Tissue Distribution, and Therapeutic Reduction-A Clinically Oriented Mechanistic Synthesis.
topicLysine Stress Randomized Trial
claimIt is the principal substrate of the glutathione-dependent GLO1/GLO2 glyoxalase system and the main source of the hydroimidazolone-1 (MG-H1) adduct, and it directly modifies intracellular proteins across multiple tissues.
evidence level4
citationFernandez EC (2026)
sourceMethylglyoxal as a Convergent Mediator of Diabetic Complications: Generation, Protein Targets, Tissue Distribution, and Therapeutic Reduction-A Clinically Oriented Mechanistic Synthesis.

Source documents

  1. Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
  2. Methylglyoxal as a Convergent Mediator of Diabetic Complications: Generation, Protein Targets, Tissue Distribution, and Therapeutic Reduction-A Clinically Oriented Mechanistic Synthesis.